Literature DB >> 23462926

Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases.

Daniel D Buchanan1, Aung K Win, Michael D Walsh, Rhiannon J Walters, Mark Clendenning, Belinda Nagler, Sally-Ann Pearson, Finlay A Macrae, Susan Parry, Julie Arnold, Ingrid Winship, Graham G Giles, Noralane M Lindor, John D Potter, John L Hopper, Christophe Rosty, Joanne P Young, Mark A Jenkins.   

Abstract

BACKGROUND: Previous reports suggest that relatives of colorectal cancer (CRC)-affected probands carrying the BRAF p.V600E mutation are at an increased risk of CRC and extracolonic cancers (ECC). In this study, we estimated the association between a family history of either CRC or ECC and risk of CRC with a BRAF p.V600E mutation.
METHODS: Population-based CRC cases (probands, ages 18-59 years at diagnosis), recruited irrespective of family cancer history, were characterized for BRAF p.V600E mutation and mismatch repair (MMR) status. ORs and 95% confidence intervals (CI) were estimated using multivariable logistic regression.
RESULTS: The 690 eligible probands showed a mean age at CRC diagnosis of 46.9 ± 7.8 years, with 313 (47.9%) reporting a family history of CRC and 53 (7.7%) that were BRAF-mutated. Probands with BRAF-mutated, MMR-proficient CRCs were less likely to have a family history of CRC than probands that were BRAF wild-type (OR, 0.46; 95% CI, 0.24-0.91; P = 0.03). For probands with a BRAF-mutated CRC, the mean age at diagnosis was greater for those with a CRC-affected first- or second-degree relative (49.3 ± 6.4 years) compared with those without a family history (43.8 ± 10.2 years; P = 0.04). The older the age at diagnosis of CRC with the BRAF p.V600E mutation, the more likely these probands were to show a family history of CRC (OR, 1.09 per year of age; 95% CI, 1.00-1.18; P = 0.04).
CONCLUSIONS: Probands with early-onset, BRAF-mutated, and MMR-proficient CRC were less likely to have a family history of CRC than probands that were BRAF-wild-type. IMPACT: These findings provide useful insights for cancer risk assessment in families and suggest that familial or inherited factors are more important in early-onset, BRAF-wild-type CRC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462926      PMCID: PMC4024397          DOI: 10.1158/1055-9965.EPI-12-1211

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  42 in total

1.  Somatic BRAF-V600E mutations in familial colorectal cancer.

Authors:  Jana Vandrovcova; Kristina Lagerstedt-Robinsson; Lars Påhlman; Annika Lindblom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

2.  Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors.

Authors:  Lauri Aaltonen; Louise Johns; Heikki Järvinen; Jukka-Pekka Mecklin; Richard Houlston
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

Review 3.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.

Authors:  J R Jass
Journal:  Histopathology       Date:  2007-01       Impact factor: 5.087

4.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Authors:  Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

Review 5.  The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature.

Authors:  Joanne Young; Jeremy R Jass
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

6.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

7.  Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.

Authors:  Jenny N Poynter; Kimberly D Siegmund; Daniel J Weisenberger; Tiffany I Long; Stephen N Thibodeau; Noralane Lindor; Joanne Young; Mark A Jenkins; John L Hopper; John A Baron; Dan Buchanan; Graham Casey; A Joan Levine; Loïc Le Marchand; Steven Gallinger; Bharati Bapat; John D Potter; Polly A Newcomb; Robert W Haile; Peter W Laird
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

8.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.

Authors:  M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic
Journal:  Fam Cancer       Date:  2007-04-24       Impact factor: 2.375

9.  Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study.

Authors:  Sean P Cleary; Michelle Cotterchio; Mark A Jenkins; Hyeja Kim; Robert Bristow; Roger Green; Robert Haile; John L Hopper; Loic LeMarchand; Noralane Lindor; Patrick Parfrey; John Potter; Ban Younghusband; Steven Gallinger
Journal:  Gastroenterology       Date:  2008-12-27       Impact factor: 22.682

Review 10.  The genetics of hereditary colon cancer.

Authors:  Anil K Rustgi
Journal:  Genes Dev       Date:  2007-10-15       Impact factor: 11.361

View more
  21 in total

Review 1.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

Review 2.  Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.

Authors:  Tsuyoshi Hamada; NaNa Keum; Reiko Nishihara; Shuji Ogino
Journal:  J Gastroenterol       Date:  2016-10-13       Impact factor: 7.527

3.  Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer?

Authors:  Rajani Bharati; Mark A Jenkins; Noralane M Lindor; Loïc Le Marchand; Steven Gallinger; Robert W Haile; Polly A Newcomb; John L Hopper; Aung Ko Win
Journal:  Gynecol Oncol       Date:  2014-03-11       Impact factor: 5.482

4.  Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine.

Authors:  Shuji Ogino; Reiko Nishihara; Tyler J VanderWeele; Molin Wang; Akihiro Nishi; Paul Lochhead; Zhi Rong Qian; Xuehong Zhang; Kana Wu; Hongmei Nan; Kazuki Yoshida; Danny A Milner; Andrew T Chan; Alison E Field; Carlos A Camargo; Michelle A Williams; Edward L Giovannucci
Journal:  Epidemiology       Date:  2016-07       Impact factor: 4.822

Review 5.  Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Authors:  Peter T Campbell; Timothy R Rebbeck; Reiko Nishihara; Andrew H Beck; Colin B Begg; Alexei A Bogdanov; Yin Cao; Helen G Coleman; Gordon J Freeman; Yujing J Heng; Curtis Huttenhower; Rafael A Irizarry; N Sertac Kip; Franziska Michor; Daniel Nevo; Ulrike Peters; Amanda I Phipps; Elizabeth M Poole; Zhi Rong Qian; John Quackenbush; Harlan Robins; Peter K Rogan; Martha L Slattery; Stephanie A Smith-Warner; Mingyang Song; Tyler J VanderWeele; Daniel Xia; Emily C Zabor; Xuehong Zhang; Molin Wang; Shuji Ogino
Journal:  Cancer Causes Control       Date:  2017-01-17       Impact factor: 2.506

6.  Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives.

Authors:  Aung Ko Win; Daniel D Buchanan; Christophe Rosty; Robert J MacInnis; James G Dowty; Gillian S Dite; Graham G Giles; Melissa C Southey; Joanne P Young; Mark Clendenning; Michael D Walsh; Rhiannon J Walters; Alex Boussioutas; Thomas C Smyrk; Stephen N Thibodeau; John A Baron; John D Potter; Polly A Newcomb; Loïc Le Marchand; Robert W Haile; Steven Gallinger; Noralane M Lindor; John L Hopper; Dennis J Ahnen; Mark A Jenkins
Journal:  Gut       Date:  2014-03-10       Impact factor: 23.059

7.  Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC).

Authors:  Mark A Jenkins; Aung Ko Win; Allyson S Templeton; Maggie S Angelakos; Daniel D Buchanan; Michelle Cotterchio; Jane C Figueiredo; Stephen N Thibodeau; John A Baron; John D Potter; John L Hopper; Graham Casey; Steven Gallinger; Loic Le Marchand; Noralane M Lindor; Polly A Newcomb; Robert W Haile
Journal:  Int J Epidemiol       Date:  2018-04-01       Impact factor: 7.196

Review 8.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

9.  Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Authors:  Shuji Ogino; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Nadine J McCleary; Kimmie Ng; Donna Niedzwiecki; Leonard B Saltz; Robert J Mayer; Renaud Whittom; Alexander Hantel; Al B Benson; Rex B Mowat; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2013-11-14       Impact factor: 13.506

10.  Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.

Authors:  Kentaro Inamura; Mingyang Song; Seungyoun Jung; Reiko Nishihara; Mai Yamauchi; Paul Lochhead; Zhi Rong Qian; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Atsuhiro Masuda; Yu Imamura; Xuehong Zhang; Michael N Pollak; Christos S Mantzoros; Curtis C Harris; Edward Giovannucci; Charles S Fuchs; Eunyoung Cho; Andrew T Chan; Kana Wu; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2015-11-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.